» Articles » PMID: 32357402

Development of Polyelectrolyte Complexes for the Delivery of Peptide-Based Subunit Vaccines Against Group A

Overview
Date 2020 May 3
PMID 32357402
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Peptide subunit vaccines hold great potential compared to traditional vaccines. However, peptides alone are poorly immunogenic. Therefore, it is of great importance that a vaccine delivery platform and/or adjuvant that enhances the immunogenicity of peptide antigens is developed. Here, we report the development of two different systems for the delivery of lipopeptide subunit vaccine (LCP-1) against group A streptococcus: polymer-coated liposomes and polyelectrolyte complexes (PECs). First, LCP-1-loaded and alginate/trimethyl chitosan (TMC)-coated liposomes (Lip-1) and LCP-1/alginate/TMC PECs (PEC-1) were examined for their ability to trigger required immune responses in outbred Swiss mice; PEC-1 induced stronger humoral immune responses than Lip-1. To further assess the adjuvanting effect of anionic polymers in PECs, a series of PECs (PEC-1 to PEC-5) were prepared by mixing LCP-1 with different anionic polymers, namely alginate, chondroitin sulfate, dextran, hyaluronic acid, and heparin, then coated with TMC. All produced PECs had similar particle sizes (around 200 nm) and surface charges (around + 30 mV). Notably, PEC-5, which contained heparin, induced higher antigen-specific systemic IgG and mucosal IgA titers than all other PECs. PEC systems, especially when containing heparin and TMC, could function as a promising platform for peptide-based subunit vaccine delivery for intranasal administration.

Citing Articles

Chitosan non-particulate vaccine delivery systems.

Masimov R, Wasan E J Pharm Pharm Sci. 2024; 27:12921.

PMID: 39114808 PMC: 11303186. DOI: 10.3389/jpps.2024.12921.


Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade.

Jin C, Zhang Y, Li B, Gao T, Wang B, Hua P Mater Today Bio. 2024; 27:101136.

PMID: 39015802 PMC: 11251012. DOI: 10.1016/j.mtbio.2024.101136.


Cyclic Peptide Conjugate Vaccines and Physically Mixed Cyclic Peptide Vaccines for Subcutaneous Immunization.

Huang W, Madge H, Toth I, Stephenson R Methods Mol Biol. 2024; 2821:111-127.

PMID: 38997484 DOI: 10.1007/978-1-0716-3914-6_9.


Polymeric Nanoparticles as Oral and Intranasal Peptide Vaccine Delivery Systems: The Role of Shape and Conjugation.

Koirala P, Shalash A, Chen S, Faruck M, Wang J, Hussein W Vaccines (Basel). 2024; 12(2).

PMID: 38400181 PMC: 10893271. DOI: 10.3390/vaccines12020198.


The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines.

Yang J, C Boer J, Khongkow M, Phunpee S, Khalil Z, Bashiri S Vaccines (Basel). 2023; 11(2).

PMID: 36851183 PMC: 9961534. DOI: 10.3390/vaccines11020305.


References
1.
Pandey M, Sekuloski S, Batzloff M . Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy. Immunol Cell Biol. 2009; 87(5):391-9. DOI: 10.1038/icb.2009.29. View

2.
Wang N, Chen M, Wang T . Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. J Control Release. 2019; 303:130-150. PMC: 7111479. DOI: 10.1016/j.jconrel.2019.04.025. View

3.
Lever R, Page C . Novel drug development opportunities for heparin. Nat Rev Drug Discov. 2002; 1(2):140-8. DOI: 10.1038/nrd724. View

4.
Hasan M, Najjam S, Gordon M, Gibbs R, Rider C . IL-12 is a heparin-binding cytokine. J Immunol. 1999; 162(2):1064-70. View

5.
Marasini N, Giddam A, Khalil Z, Hussein W, Capon R, Batzloff M . Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery. Nanomedicine (Lond). 2016; 11(24):3223-3235. DOI: 10.2217/nnm-2016-0291. View